Pharmaron Beijing (300759) Stock Overview
Operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
300759 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Pharmaron Beijing Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥35.75 |
| 52 Week High | CN¥37.63 |
| 52 Week Low | CN¥20.47 |
| Beta | 0.98 |
| 1 Month Change | 20.57% |
| 3 Month Change | 46.28% |
| 1 Year Change | 17.79% |
| 3 Year Change | -0.79% |
| 5 Year Change | -24.04% |
| Change since IPO | 629.26% |
Recent News & Updates
Recent updates
Why Pharmaron Beijing Co., Ltd. (SZSE:300759) Could Be Worth Watching
Mar 17
Pharmaron Beijing (SZSE:300759) Takes On Some Risk With Its Use Of Debt
Mar 02Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Price Is Right But Growth Is Lacking
Jan 15A Look At The Intrinsic Value Of Pharmaron Beijing Co., Ltd. (SZSE:300759)
Dec 31Pharmaron Beijing (SZSE:300759) Has A Somewhat Strained Balance Sheet
Dec 01At CN¥29.44, Is It Time To Put Pharmaron Beijing Co., Ltd. (SZSE:300759) On Your Watch List?
Nov 15Shareholder Returns
| 300759 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 6.5% | 5.3% | 1.8% |
| 1Y | 17.8% | 62.5% | 24.1% |
Return vs Industry: 300759 underperformed the CN Life Sciences industry which returned 62.4% over the past year.
Return vs Market: 300759 underperformed the CN Market which returned 24.1% over the past year.
Price Volatility
| 300759 volatility | |
|---|---|
| 300759 Average Weekly Movement | 7.0% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 300759 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300759's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 22,908 | Boliang Lou | www.pharmaron.com |
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development.
Pharmaron Beijing Co., Ltd. Fundamentals Summary
| 300759 fundamental statistics | |
|---|---|
| Market cap | CN¥60.73b |
| Earnings (TTM) | CN¥1.38b |
| Revenue (TTM) | CN¥13.11b |
Is 300759 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300759 income statement (TTM) | |
|---|---|
| Revenue | CN¥13.11b |
| Cost of Revenue | CN¥8.61b |
| Gross Profit | CN¥4.50b |
| Other Expenses | CN¥3.12b |
| Earnings | CN¥1.38b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 29, 2025
| Earnings per share (EPS) | 0.78 |
| Gross Margin | 34.32% |
| Net Profit Margin | 10.53% |
| Debt/Equity Ratio | 37.3% |
How did 300759 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 08:10 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharmaron Beijing Co., Ltd. is covered by 28 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Jin Zhang | China International Capital Corporation Limited |